ASCO® 2023 Insights: "FGFR 2.0 in BTC - Is There a Best in Class?"

Insights from 2023 ASCO® Annual Meeting

A. Vogel

ASCO® 2023 Insights: "IMbrave050 Data on Atezolizumab + Bevacizumab …

ecancer

M. Kudo

ASCO® 2023 Insights: "ATTRACTION-5 Study on Nivo + Chemo as Postoper…

ecancer

M. Terashima

Precision Medicine and IO Have Arrived for Cholangiocarcinoma: An Ov…

Penn Medicine Abramson Cancer Center

T. Karasic

Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions

Arndt Vogel

Great Debate: Neoadjuvant vs. Adjuvant Therapy for High-Risk BTC - P…

2023 Johns Hopkins Updates in Gastrointestinal Cancers

T. Karasic

Managing Treatment-Related Side Effects in GI Cancers: Chemo, Target…

2023 Johns Hopkins Updates in Gastrointestinal Cancers

P. Griffith

Medical Oncology Updates in BTC

2023 Johns Hopkins Updates in Gastrointestinal Cancers

M. Baretti

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Importance of Molecular Profiling in Biliary Tract Cancer

Milind Javle

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

ASH 2022 Conference Coverage

A. Vannucchi

Myeloid/Lymphoid Neoplasms With Fusion Tyrosine Kinase Genes: Treatm…

Prithviraj Bose

ASCO GI 2023 Phase 3 Randomized SWOG 1815 Trial: Gemcitabine, Cispla…

ASCO GI 2023 Conference Coverage

R. Shroff

ASCO GI 2023 Evaluation of Clinical Benefit and PFS Ratio of Targete…

ASCO GI 2023 Conference Coverage

M. Niger

SOHO 2022: Novel Therapies for Eosinophilia

SOHO 2022 Tenth Annual Meeting

E. Hexner

Targeted Therapies for Cholangiocarcinoma

Lorenza Rimassa

Cholangiocarcinoma: Disease Overview, Diagnosis, and Treatment Optio…

MedNews Week

J. Cleary